A recent study has sparked discussions about the potential risks associated with certain contraceptives, particularly those containing progestogens. The research, published in JAMA Network Open, analyzed data from approximately 3 million women in Denmark and found a link between progestogen-containing contraceptives and an increased risk of developing meningioma, a type of brain tumor. This finding adds to a growing body of evidence suggesting that the association extends beyond injectable depot medroxyprogesterone acetate (DMPA) to include certain oral contraceptives and high-dose levonorgestrel intrauterine devices (IUDs).
The study's findings are significant because they highlight the importance of individualized counseling when selecting contraceptive therapy. While the absolute risk of developing meningioma remains low, the relative risk is higher among current users or those who have used these contraceptives within the previous year. Encouragingly, the excess risk generally disappeared 5 years after discontinuation of the contraceptive.
Pharmacists and other healthcare professionals play a crucial role in shared decision-making. They should help patients understand the distinction between relative and absolute risk and emphasize that the absolute risk is very low and should be individualized based on patient risk factors and other conditions. When counseling patients, clinicians should continue weighing contraceptive benefits alongside potential risks, considering factors such as hormone formulation, dose, route of administration, duration of therapy, and patient-specific risk factors.
The study's findings should not be interpreted to mean that hormonal contraceptives broadly cause brain tumors. Instead, they reinforce the importance of individualized counseling when selecting contraceptive therapy. Similar to discussions surrounding menopausal hormone therapy and breast cancer risk, clinicians must consider differences in hormone formulation, dose, route of administration, duration of therapy, and patient-specific risk factors before making treatment decisions.
Biologically, the association is considered plausible because progesterone receptors are expressed in up to 87% of meningiomas, and previous studies have observed tumor growth during pregnancy or exogenous progesterone exposure, with regression following hormone withdrawal.
In conclusion, the study's findings provide clinically relevant information for both prescribers and patients but should be interpreted within the context of the rarity of meningioma and the well-established benefits of effective contraception. Healthcare professionals should continue to weigh the risks and benefits of contraceptive options for each patient, ensuring that the decision is individualized and based on the patient's needs and other conditions.
